login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SUPERNUS PHARMACEUTICALS INC (SUPN) Stock News
USA
- NASDAQ:SUPN -
US8684591089
-
Common Stock
55.13
USD
-1.37 (-2.42%)
Last: 10/31/2025, 8:15:13 PM
55.5
USD
+0.37 (+0.67%)
After Hours:
10/31/2025, 8:15:13 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SUPN Latest News, Press Relases and Analysis
All
Press Releases
5 days ago - By: Chartmill
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Emerges as a Top Affordable Growth Candidate
17 days ago - By: Chartmill
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Presents a Compelling Mix of Growth and Technical Momentum
3 days ago - By: Zacks Investment Research
- Mentions:
AMPH
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
4 days ago - By: Zacks Investment Research
- Mentions:
BBIO
BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates
4 days ago - By: Zacks Investment Research
Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy
6 days ago - By: Zacks Investment Research
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run?
10 days ago - By: Benzinga
Deep Dive Into Supernus Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)
12 days ago - By: Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
12 days ago - By: Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
20 days ago - By: Zacks Investment Research
Supernus Pharmaceuticals (SUPN) Is Up 2.81% in One Week: What You Should Know
23 days ago - By: Zacks Investment Research
- Mentions:
NVS
BIIB
PTCT
Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?
24 days ago - By: Benzinga
- Mentions:
KTOS
TSCO
PNC
SF
...
Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday
2 months ago - By: Biogen Inc.
- Mentions:
BIIB
Biogen Receives European Commission Approval for ZURZUVAEĀ® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
2 months ago - By: Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals to Participate in September Investor Conferences
2 months ago - By: Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals to Participate in September Investor Conferences
Please enable JavaScript to continue using this application.